Mood Disorders and Substance Use Disorder: A Complex Comorbidity

Mood disorders, including depression and bipolar disorders, are the most common psychiatric comorbidities among patients with substance use disorders. Treating patients’ co-occurring mood disorders may reduce their substance craving and taking and enhance their overall outcomes. A methodical, staged screening and assessment can ease the diagnostic challenge of distinguishing symptoms of affective disorders from manifestations of substance intoxication and withdrawal. Treatment should maximize the use of psychotherapeutic interventions and give first consideration to medications proven effective in the context of co-occurring substance abuse. Expanded communication and collaboration between substance abuse and mental health providers is crucial to improving outcomes for patients with these complex, difficult co-occurring disorders.

Mood or affective disorders, as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), are classified as depressive or bipolar (Table 1). During the past decade, research results and clinical experience have converged in the recognition that these psychiatric illnesses commonly co-occur with substance use disorders (SUDs) and that the combination has adverse clinical consequences. Mood and SUD comorbidity downgrades the clinical course, treatment outcome, and prognosis for each problem. Theoretically, the converse is also likely to be true: Successful alleviation of one condition should facilitate recovery from the other. Some evidence indicates that treating a comorbid affective disorder can decrease substance abuse and craving (Cornelius et al., 1997).

Researchers and clinicians have begun to develop treatment approaches that address both disorders simultaneously, with early indications of efficacy. This article explores the prevalence and relationship of co-occurring mood disorders and SUDs, describes a methodical approach to assessment, and reviews evidence-based psychotherapeutic and pharmacotherapeutic treatments.

EPIDEMIOLOGICAL RELATIONSHIPS

Two epidemiological studies have examined the prevalence of psychiatric and substance use disorders by conducting diagnostic interview surveys in representative community samples of adults: the National Institute of Mental Health Epidemiologic Catchment Area (ECA) Study (Regier et al., 1990) conducted in...
the early 1980s and the National Comorbidity Survey (NCS) conducted in 1991 (Kessler et al., 1994). Both provided striking documentation that mood disorders increase the risk of SUD.

In one study, individuals with depression were twice as likely to have a substance abuse problem. In the ECA Study, the lifetime prevalence rate for any non-SUD mental disorder was estimated to be 22.5 percent, compared with 13.5 percent for alcohol abuse/dependence and 6.1 percent for other drug abuse/dependence (Regier et al., 1990). Among individuals with a mood disorder, 32 percent had a co-occurring SUD. Of individuals with lifetime major depression, 16.5 percent had an alcohol use disorder and 18 percent had a drug use disorder. SUDs were particularly common among individuals with bipolar disorder—56 percent had a lifetime SUD.

In the NCS, the lifetime prevalence estimate for any mental disorder was 48 percent (Kessler et al., 1997). The estimate for alcohol dependence was 14.1 percent, and for drug dependence 7.5 percent. The lifetime prevalence rate for any mood disorder was 19.3 percent. Compared with individuals with no mood disorders, those with depression were approximately twice as likely, and those with bipolar disorder approximately seven times as likely, to have an SUD. (The ECA study also documented a high rate of co-occurrence of SUD, mood, and anxiety disorders; while anxiety disorders are clinically common and important, they are a separate category of illness and discussion of them is beyond the scope of this paper.)

Substance abuse sometimes ‘unmasks’ mood disorders by increasing symptom severity to clinically significant levels. Clinicians may reach different conclusions, depending on when they conduct assessments relative to the patient’s entry into treatment.

**Why Are These Comorbidities so Common?**

The major mood disorders and their key clinical features can be found in Table 1. Several theories have been proposed to explain the high co-occurrence of substance abuse and mood disorders. In general, they fall into three categories.

**Disorder Fostering Disorder**

One theory proposes that the pathological effects of a mood disorder or SUD may increase risk for the other. For example, mood disorders may motivate individuals to resort to drugs and alcohol to cope with their negative affective states. Such an explanation would jibe with clinicians’ everyday experience of individuals with SUDs saying they use drugs and alcohol to combat unwanted moods. The substances may initially minimize or moderate the mood symptoms, but withdrawal and chronic abuse typically exacerbate mood degradation, leading to increasing abuse and ultimately dependence.

The self-medication explanation implies that individuals will tend to select drugs that alleviate their specific psychiatric symptoms. For example, some psychologists suggest that people with uncontrollable feelings of rage and aggression may choose opiates for these drugs’ mellowing effects, while people who are depressed may take cocaine because it exhilarates and energizes them. Studies showing such associations between abusers’ drugs of choice and their psychiatric diagnoses or symptoms would strengthen the evidence for the self-medication model, but to date few have been published.

While the self-medication model suggests that mood disorders increase the risk of substance abuse, the converse is also possible. Chronic substance abuse sometimes “unmasks” bipolar or other mood disorders—that is, triggers an increase in symptom severity from a subclinical to a clinically significant level. This appears to occur because in genetically vulnera-
ble individuals, the drugs exacerbate pathophysiological changes in neurotransmitter systems or signaling pathways that already are abnormal and underlie the mood disorder (Markou, Kosten, and Koob, 1998).

**Overlapping Neurobiological Pathways**

Another proposed explanation for the high comorbidity rate of mood disorders with SUDs involves “kindling.” The term, usually associated with epilepsy, refers to the concept that repeated disruptions, such as occur during seizures, sensitizes brain cells. The more sensitized the neurons become, the less it takes to disrupt them, which is why in untreated epilepsy, seizures tend to become more frequent and severe over time. Both alcohol and cocaine sensitize neurons, and this increased sensitivity may contribute to the typical progression from occasional to increasingly frequent and intense use of these substances. Mood disorders often follow a similar course of increasingly distressing symptomatic episodes separated by progressively shorter periods of remission, suggesting that they too may intensify via a kindling process (Post, Rubinow, and Ballenger, 1984). The kindling explanation for comorbidity, then, holds that in vulnerable individuals, an underlying neurobiological tendency to sensitization may promote both drug dependence and mood disorders.

**Underlying Genetic Factors**

Research has definitively shown that both substance abuse and mood disorders have genetic risk factors. In addition, families with substance abusers are more likely than those without to also have members with mood disorders, and vice versa. These facts raise the possibility that some gene variants may contribute to the risk for both types of illness. A person’s genes might:

- make him or her vulnerable to mood disorders, which he or she might then try to self-medicate, as discussed above;
- shape the brain so that it responds to initial drug exposures in ways that promote chronic substance abuse, with the drugs then wreaking changes that lead to mood disorders;
- cause the brain to develop in a way that directly fosters both types of disorder, for example through vulnerability to neuronal sensitization and kindling.

**Diagnostic Confounding**

Some portion of the reported high co-occurrence of SUD and mood disorders may represent confounding of mood disorders and transient symptoms related to acute abuse and withdrawal. Drug abuse symptoms can mimic symptoms of both depression and mania. Acute alcohol and stimulant intoxication can produce symptoms of mania or hypomania, and substance withdrawal often manifests as symptoms of dysphoria and depression. Chronic use of central nervous system (CNS) stimulants, such as cocaine and amphetamines, may produce symptoms that are typical of bipolar spectrum disorders, such as euphoria, increased energy, decreased appetite, grandiosity, and paranoia.

Conversely, withdrawal from CNS stimulants (especially cocaine) can give rise to anhedonia (inability to feel pleasure), apathy, depressed mood, and suicidal

---

**TABLE 1. DSM-IV MOOD DISORDER CATEGORIZATION**

| DISORDER CATEGORY | DISORDER TYPE | KEY FEATURES |
|-------------------|--------------|--------------|
| Depressive Disorders (no history of manic,* mixed manic,** or hypomanic*** episodes) | Major depressive disorder | 2-week duration, with depressed mood/loss of interest |
| | Dysthymic disorder | Chronic, less severe than MDD; 2-year duration |
| Bipolar Disorders (manic,* mixed,** or hypomanic*** episodes plus major depressive episodes) | Bipolar I | One or more manic/mixed and depressive episode |
| | Bipolar II | One or more depressive and at least one hypomanic episode |
| | Cyclothymia | Chronic/less severe form of bipolar disorder; 2-year duration, with multiple periods of hypomania/depression |
| Substance-Induced Mood Disorder | | Prominent and persistent mood disturbance, direct physiologic consequence of substance use |

---

* Manic episode: abnormally elevated/expansive/irritable mood for at least 1 week.
** Mixed episode: meets criteria for manic and depressed episode daily for 1 week.
***Hypomanic episode: elevated/expansive/irritable mood for at least 4 days—little functional impairment.
A good strategy is to screen patients upon intake to identify those whose condition warrants more careful assessment and followup. The Symptom Checklist (SCL-90) is a widely used instrument that has reasonable validity in detecting general distress as an indicator of psychiatric illness, but does not provide information about specific psychiatric diagnoses. The SCL-90 has high sensitivity and moderate specificity for anxiety and mood disorders in substance abuse patients, which are good characteristics for a screen: It will let few patients with these problems slip by, while false positives will be identified at the more thorough follow-up assessment. The Addiction Severity Index (ASI) is sometimes used in substance abuse treatment settings to guide treatment planning. This instrument has a psychiatric subscale score that detects general distress reasonably well. In one study, this subscale score correlated with SCL-90 scores in a group of substance-dependent women (Comfort et al., 1999). The Beck Depression Inventory (BDI) is another brief self-report instrument with demonstrated utility in detecting depression in substance abuse treatment settings.

Before attempting a definitive diagnostic assessment, it is best to wait until the patient has had a reasonable period of abstinence. Doing so gives symptoms of acute intoxication and withdrawal time to subside. For example, a number of studies have found a 30 to 50 percent decrease in depression rating scores from the first day of abstinence to the end of the second week (Goldsmith and Ries, 2003). The appropriate minimum abstinence interval varies, depending on both the diagnosis under consideration and the substance of abuse. Long-acting drugs (e.g., diazepam, methadone) require longer abstinence prior to diagnosis than do shorter acting compounds (e.g., alcohol, cocaine). For individuals on methadone, a confident diagnosis can generally be made and treatment initiated if mood symptoms persist after 4 weeks on a stable maintenance dosage.

During abstinence pending diagnostic assessment, patients with symptoms indicating possible mood disorders generally need support and supervision. Some require observation in an inpatient setting, either due to symptoms of withdrawal that require treatment in a controlled environment or because of psychiatric symptoms such as suicidality or mania. When patients show severe symptoms of depression, mania, or hypomania, immediate treatment rather than continued waiting may be necessary to relieve suffering and facilitate treatment engagement.

The symptoms and history should be weighed carefully together in the diagnostic assessment. Guiding principles are:

- If a patient’s symptoms seem typical of intoxication or withdrawal from a drug the patient has been abusing, especially with no previous psychiatric history, that is probably all they are. Expect them to remit soon, generally within days.
- Patients who have substance-induced mood disorders exhibit symptoms that result directly from the lingering physiological effects of the substance of abuse. Their affective difficulties commence within 4 weeks of last exposure to the substance, but are more severe and long-lasting than those normally associated with intoxication or withdrawal.
- Patients with underlying preexisting mood disorders may experience symptoms of varying type and intensity at any time during withdrawal or treatment. A strong family history of mood disorder makes diagnosis of a primary mood disorder more likely, as do a patient history showing onset of symptoms prior to substance abuse, severity of symptoms exceeding that normally seen in intoxication and
withdrawal, and sustained mood symptoms following lengthy abstinence.

**CLINICAL COURSE AND TREATMENT**

Studies indicate that individuals with SUD and a mood disorder have a more severe clinical course and worse outcomes than individuals who have only one or the other. Alcohol and drug abuse are associated with mood destabilization in individuals with affective disorders (Markou, Kosten, and Koob, 1998). Keller and colleagues (1986) found that among a group of bipolar patients, those with alcohol dependence recovered more slowly than those without. In comparing the histories of individuals with bipolar disorder, Sonne and colleagues (1994) found that those who also were substance abusers had an earlier age of onset of bipolar episodes, more frequent hospitalizations, and more comorbid psychiatric disorders. Hasin and colleagues (2002) studied the timing of depressive episodes relative to remission and relapse to substance abuse. They found that current substance-induced major depressive disorder (MDD), a history of MDD prior to the onset of substance dependence, or a depressive episode experienced during a 4-week initial abstinence reduced the odds that the patient would achieve 6 months of continuous abstinence.

A tragic association between SUDs, mood disorders, and suicide has long been recognized. The disinhibition and despair often associated with intoxication likely set the stage for impulsive and self-destructive acts. In one study, two-thirds of individuals who committed suicide had an SUD (Rich, Fowler, and Young, 1989). In comparing a number of psychiatric diagnostic groups, Young and colleagues (1994) found that individuals with MDD co-occurring with alcohol and drug dependence were at the highest risk for suicide.

In sum, substance abuse appears to have an adverse impact on the course and prognosis of mood disorders, leading to more frequent hospitalizations and treatment-resistant symptoms. On the other hand, some data indicate that alleviation of mood symptoms can improve substance-abuse-related outcomes.

In general, treatment efforts addressing mood disorders and SUDs have developed in parallel. Integration of services and effective treatment strategies from both fields can optimize outcomes when the two disorders converge.

**Psychotherapeutic Treatment**

Maximum use of behavioral approaches is the first principle of treatment for patients with SUD and a concurrent mood disorder. First, learning and gaining self-confidence in one’s ability to self-regulate subjective states can be extremely helpful in recovery from both disorders. Second, learning strategies to self-regulate mood symptoms may help patients to break out of the mindset of using external agents to combat intolerable subjective states.

The behavioral strategies used for patients with co-occurring disorders should include elements of proven efficacy for each. Cognitive-behavioral therapies (CBTs) are among the most effective psychosocial treatments for affective disorders and also have demonstrated efficacy in the treatment of SUDs. Several recently published pilot studies have validated psychotherapeutic strategies specifically designed for individuals with co-occurring disorders. In a study of depressed alcoholics who received standard alcohol treatment plus either CBT for depression or relaxation training (control group), the CBT group showed greater improvements in depressive symptoms during treatment and also had better drinking outcomes at 3- and 6-month followup visits (Brown et al., 1997).

Weiss and colleagues (2000) compared a manual-based CBT group therapy with treatment as usual for patients with SUD and bipolar disorder, and found that CBT produced significantly better outcomes in a number of domains. A large treatment-matching study of alcohol-dependent individuals compared three psychosocial interventions: 12-step facilitation, CBT, and brief motivational therapy. The treatments were equally effective overall; however, patients with high psychopathology as assessed by the ASI had better outcomes with CBT than with 12-step facilitation (Project MATCH Research Group, 1997).

Active participation in Alcoholics Anonymous (AA) or Narcotics Anonymous (NA) can greatly enhance recovery. Clinicians should encourage patients with co-occurring disorders to affiliate with 12-step groups that give clear, positive messages about the use of prescribed psychotropic medications. Recognition of the prevalence of co-occurring disorders has led to the establishment of a number of self-help groups for dual-diagnosis patients modeled on AA and NA, such as Double-Trouble and Dual Recovery Anonymous. While this development holds promise, the efficacy of these groups needs to be systematically explored.
TABLE 2. MEDICATIONS USED FOR THE TREATMENT OF MOOD DISORDERS IN SUBSTANCE ABUSERS

| MOOD DISORDER | AGENTS USED | AGENTS TO AVOID |
|---------------|-------------|-----------------|
| Depression    | Serotonin Reuptake Inhibitors  
Fluoxetine (Prozac)  
Sertraline (Zoloft)  
Paroxetine (Paxil)  
Citalopram (Celexa)  
Escitalopram (Lexapro)  
Tricyclic Antidepressants  
Imipramine (Tofranil)  
Nortriptyline (Pamelor)  
Other  
Venlafaxine (Effexor)  
Bupropion (Wellbutrin)  | Monoamine Oxidase Inhibitors  
Tranylcypromine (Parate)  
Phenelzine (Nardil)  |
| Bipolar Disorder | Mood Stabilizers  
Lithium (Eskalith)  
Valproate (Depakote)  
Lamotrigine (Lamictal)  
Atypical Antipsychotics  
Olanzapine (Zyprexa)  
Risperidone (Risperdal)  
Typical Antipsychotics  
Haloperidol (Haldol)  
Benzodiazepines*  
Clonazepam (Klonopin)  | Benzodiazepines  
Diazepam (Valium)  
Alprazolam (Xanax)  
Stimulants  
Methylphenidate (Ritalin)  |

* Long-term use of benzodiazepines should be avoided.

Pharmacotherapy

The past 10 years have seen an explosion of new psychotherapeutic medications with enhanced efficacy and tolerability. Treatment options have increased for individuals with SUDs and those with mood disorders, yet few studies have evaluated the new agents in individuals who have both concurrently.

Even when community programs diagnose or suspect mood disorders, they often lack clinicians who can prescribe medications on site. In one recent study, McLellan and colleagues (2003) found that fewer than half of the Nation’s drug and alcohol treatment programs had a full-time physician or nurse. Considering the prevalence of co-occurring disorders, developing strong collaborative relationships between addiction treatment professionals and local physicians and mental health centers is critical for optimizing patient outcomes.

Medicating Depression

As discussed, prudence usually dictates waiting to start a patient with SUD on a medication for depressed mood until after detoxification. Doing so avoids unnecessarily exposing the patient to the expense and risk of medications when his or her symptoms may resolve of themselves in days or weeks. As well, it removes the possibility of confounding symptoms of withdrawal with side effects of the antidepressant medication. The most common symptoms of substance withdrawal—anxiety, agitation, sedation, nausea, and headache—are also potential side effects of the agents commonly used to treat depression, such as the serotonin reuptake inhibitors (SRIs; e.g., sertraline), venlafaxine, and bupropion. Nevertheless, if depression is severe and shows little sign of remitting within the first few days of abstinence, and if risk factors are present to suggest that a mood disorder may underlie it (e.g., a positive family history of MDD), early pharmacotherapeutic intervention may be justified. Table 2 lists the medications most frequently used to treat mood disorders, as well as medications that individuals with SUDs should avoid.

Recently, Núñes and Levin (2004) presented a systematic review and meta-analysis of studies of antidepressant medications in the treatment of co-occurring depression and SUDs. While over 300 studies have explored this issue, only 14 were placebo-controlled trials that included subjects meeting recognized diagnostic criteria for depression and SUD. Of the 14, five used tricyclic antidepressants (TCAs), seven used SRIs, and two used other types of antidepressant agents. The results varied widely, with eight studies reporting significant or trend antidepressant effects and the rest finding none. Overall, the authors concluded that antidepressant medications demonstrated a modest beneficial effect for patients with combined depression and SUD. The finding of efficacy was more robust for studies of alcohol-dependent individuals than of drug-dependent individuals. Among the studies that demonstrated a decrease in depression, medication also had a favorable effect on substance abuse.
Nuñes and Levin also found that studies using TCAs yielded more positive results than those using SRIs, although they noted that this finding must be interpreted with caution since:

- the negative SRI studies had high placebo response rates, and
- the SRI studies that were positive demonstrated substantial medication effects on both depression and substance abuse.

In their final analysis, the authors concluded that SRIs should be the first-line medications for depression when SUD is also present based on their favorable tolerability and low toxicity compared to the TCAs. Other new classes of antidepressant drugs, like venlafaxine and bupropion, have shown promise in pilot studies with individuals with comorbid depression and SUDs and warrant further investigation.

While antidepressant medications may be useful, interventions to promote recovery from addictions and stabilize the environment are essential parts of successful treatment. A recent study starkly demonstrated this point: In a controlled trial with depressed individuals in methadone maintenance for opioid addiction, sertraline demonstrated significant effects in ameliorating depression and decreasing drug use only in those subjects who had more positive environments—i.e., more social and familial contact, better employment and monetary resources, and fewer legal problems and interpersonal conflicts (Carpenter et al., 2004).

**Medicating Bipolar Disorder**

While individuals with bipolar I disorder often receive treatment in mental health rather than addiction settings, the more subtle forms of bipolar disorder (bipolar II, cyclothymia) are more common than previously appreciated (Hirschfeld et al., 2003). Compared with bipolar I disorder, bipolar spectrum disorders are more difficult to distinguish from substance-induced mood symptoms and may be more likely to present in the addiction treatment setting. As with depression, the most accurate diagnostic assessment can be made after a period of abstinence. For bipolar patients in particular, a close working relationship with mental health care providers and/or psychiatric consultants will be essential to providing optimal care.

Despite the relatively frequent co-occurrence of SUD and bipolar disorder, few studies have focused on pharmacological therapy for patients with this dual diagnosis. Several small pilot studies have shown that patients with bipolar-SUD comorbidity benefit from valproate and tolerate it well (Albanese, Clodfelter, and Khantzian, 2000; Brady et al., 1995; Hertzman, 2000). In one such study, this population tolerated and adhered to valproate better than to lithium (Weiss et al., 1998). A recent double-blind placebo-controlled trial examining actively drinking bipolar individuals treated with valproate versus placebo, with both groups also receiving lithium and psychosocial intervention, documented lower alcohol consumption with valproate (LeFauve et al., 2004). While valproate did not produce superior mood outcomes, there was a trend for individuals receiving it to remit from mania sooner. A recent open-label trial by the same investigators found that valproate plus naltrexone outperformed valproate alone in reducing substance abuse (0 percent versus 75 percent relapse rate) as well as mood symptoms (Salloum, Cornelius, and Chakravorty, 2003). Additionally, carbamazepine has been shown in one study to reduce cocaine abuse in persons with cocaine dependence and affective disorder (Brady et al., 2002).

Individuals who have bipolar disorder complicated by SUD are more likely to experience mixed episodes of depression and mania and rapid cycling between the two (Sonne and Brady, 1999). In patients with uncomplicated bipolar disorder, both characteristics predict a better response to anticonvulsant mood-stabilizing agents (e.g., valproate, carbamazepine, lamotrigine) than to lithium (Swann et al., 1999, 2002). Accordingly, some specialists have hypothesized that substance-abusing bipolar patients should receive an anticonvulsant rather than lithium as a first-line therapy. This may be a reasonable approach, but lithium can also be effective: A small placebo-controlled trial with 25 adolescents with bipolar disorder and SUDs yielded significant associations between lithium therapy, reduced drug abuse, and improved mood symptoms (Geller et al., 1998).

With respect to other medications used to treat bipolar disorder, no controlled studies to date have evaluated the use of olanzapine in patients with bipolar-SUD comorbidity. In one reported case involving three patients, olanzapine reduced substance abuse, cravings, and anxiety (Sattar et al., 2003). In a recently conducted open-label trial, lamotrigine treatment brought improvement in bipolar symptoms and...
decreased cocaine craving, but did not have a significant effect on drug abuse (Brown et al., 2003). Although the pharmacotherapeutic treatment of comorbid bipolar disorder and SUDs clearly needs further elucidation, research has opened a number of promising avenues for development.

CONCLUSIONS
Co-occurrence of SUD and affective disorders is common and has an impact on prognosis and treatment. Diagnosis and assessment of these comorbid disorders are difficult because of the substantial overlap in the symptoms of substance intoxication, withdrawal, and mood disorders. Using screening instruments to identify individuals with possible mood disorders and following up after a period of abstinence may be a particularly useful approach for busy clinicians.

Several treatment approaches have been developed specifically for patients with SUD and depression or bipolar disorder, and manuals for these approaches are available. While the use of complex manual-guided therapies may not be practical in some community treatment settings, these studies and others now under way should establish the critical components and techniques of effective treatment for these patients. The best approach to implementing these treatments in practice is an area that requires further exploration.

Recent advances in the pharmacotherapy of mood disorders benefit the population with co-occurring disorders because the newer agents have less toxicity, fewer side effects, and fewer interactions with substances of abuse. While few studies have specifically evaluated pharmacotherapy in dual-diagnosis patients, the results to date indicate that similar medications are effective for mood disorders, whether or not SUD also is present. Moreover, treatment of mood disorders may be associated with decreased substance abuse. Clearly, specific considerations in choosing a pharmacologic agent for use in patients with SUD include safety, toxicity, and abuse liability.

While recent advances have identified specific therapeutic options for individuals with co-occurring SUDs and mood disorders, circumstances in both the mental health and addiction treatment systems make the delivery of optimal care difficult. In a recent study of the national addiction treatment infrastructure, McLellan and colleagues (2003) found that staff turnover was high, fewer than one-half of programs had a full-time nurse or physician, and very few programs had a social worker or psychologist. Given these constraints, expanding communication and collaboration between agencies and health care providers is vital to providing optimal care for patients with co-occurring disorders.

ACKNOWLEDGMENT
This work was supported by NIDA grants U10-DA-1-3727 and K24-DA-0-0435.

CORRESPONDENCE
Kathleen T. Brady, M.D., Ph.D., Professor of Psychiatry, Medical University of South Carolina, Institute of Psychiatry, Clinical Neuroscience, 67 President Street, Charleston, SC 29425; e-mail: bradyk@musc.edu.
REFERENCES

Albanese, M.J.; Clodfelter, R.C. Jr.; and Khantzian, E.J., 2000. Divalproex sodium in substance abusers with mood disorder. Journal of Clinical Psychiatry 61(12):916-924.

Brady, K.T., et al., 1995. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study. Journal of Clinical Psychiatry 56(3):118-121.

Brady, K.T., et al., 2002. Carbamazepine in the treatment of cocaine dependence: Subtyping by affective disorder. Experimental and Clinical Psychopharmacology 10(3):275-285.

Brady, K.T.; Myrick, H.; and Sonne, S., 1993. Comorbid addiction and affective disorders. In: A.W. Graham, T.K. Schultz, and B.B. Wilford (Eds.), Principles of Addiction Medicine (2nd ed.). Arlington, VA: American Society of Addiction Medicine, pp. 983-992.

Brown, E.S., et al., 2003. Lamotrigine in patients with bipolar disorder and cocaine dependence. Journal of Clinical Psychiatry 64(2):197-201.

Brown, R.A., et al., 1997. Cognitive-behavioral treatment for depression in alcoholism. Journal of Consulting and Clinical Psychology 65(3):715-726.

Carpenter, K.M., et al., 2004. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: A controlled clinical trial. Drug and Alcohol Dependence 74:123-134.

Comfort, M., et al., 1999. Assessing the needs of substance abusing women. Psychometric data on the psychosocial history. Journal of Substance Abuse Treatment 17:79-83.

Cornelius, J.R., et al., 1997. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Archives of General Psychiatry 54(8):700-705.

Coller, B., et al., 1998. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Adolescent Psychiatry 37(2):171-178.

Goldsmith, R.J., and Ries, R.K., 2003. Substance-induced mental disorders. In: A.W. Graham, T.K. Schultz, R.K. Ries, and B.B. Wilford (Eds.), Principles of Addiction Medicine (3rd ed.). Chevy Chase, MD: American Society of Addiction Medicine, pp. 2123-2126.

Hasin, D., et al., 2002. Effects of major depression on remission and relapse of substance dependence. Archives of General Psychiatry 59(4):375-380.

Hertzman, M., 2000. Divalproex sodium to treat concomitant substance abuse and mood disorders. Journal of Substance Abuse Treatment 18(4):371-372.

Hirschfield, R.M., et al., 2003. Validity of the mood disorder questionnaire: A general population study. American Journal of Psychiatry 160(1):178-180.

Keller, M.B., et al., 1986. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up. American Journal of Psychiatry 143(1):24-28.

Kessler, R.C., et al., 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51(1):8-19.

Kessler, R.C., et al., 1997. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 54(4):313-321.

LeFauve, C.E., et al., 2004. Pharmacological treatment of alcohol dependence/psychiatric comorbidity. Alcoholism: Clinical and Experimental Research 28(2):302-312.

Markou, A.; Kosten, T.R.; and Koob, G.F., 1998. Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 19(3):135-174.

McLellan, A.T.; Canse, D.; and Kleber, H.D., 2003. Can the national addiction treatment infrastructure support the public’s demand for quality care? Journal of Substance Abuse Treatment 25:117-121.

Nuñes, E.V., and Levin, F.R., 2004. Treatment of depression in patients with alcohol or other drug dependence. A meta-analysis. Journal of the American Medical Association 291(15):1887-1896.

Post, R.M.; Rubinow, D.R.; and Ballenger, J.C., 1984. Conditioning, sensitization, and kindling: Implications for the course of affective illness. In: R.M. Post and J.C. Ballenger (Eds.), Neurobiology of Mood Disorders. Baltimore, MD: Williams and Wilkins, pp. 432-466.

Project MATCH Research Group, 1997. Matching alcohol treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. Journal of Studies on Alcohol 58(1):7-29.

Regier, D.A., et al., 1990. Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association 264(19):2511-2518.

Rich, C.L.; Fowler, R.C.; and Young, D., 1989. Substance abuse and suicide: The San Diego suicide study. Annals of Clinical Psychiatry 2(2):79-85.

Rounsaville, B.J., et al., 1991. Psychiatric diagnoses of treatment seeking cocaine abusers. Archives of General Psychiatry 48(1):43-51.

Salloum, I.M.; Cornelius, J.R.; and Chakravorthy, S., 2003. Utility of combined naltrexone valproate treatment in bipolar alcoholics: A randomized, open-label, pilot study. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June 21-25, 2003. I. Diamond (Ed.): Baltimore, MD: Lippincott, Williams & Wilkins, pp. 843, 146A.

Sattar, S.P., et al., 2003. Potential use of olanzapine in treatment of substance dependence. Journal of Clinical Psychopharmacology 23(4):413-414.

Sonne, S.C., and Brady, K.T., 1999. Substance abuse and bipolar comorbidity. Psychiatric Clinics of North America 22(3):609-627.

Sonne, S.C.; Brady, K.T.; and Morton W.A., 1994. Substance abuse and bipolar affective disorder. Journal of Nervous and Mental Disease 182(6):349-352.

Swann, A.C., et al., 1999. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. American Journal of Psychiatry 156(8):1264-1266.

Swann, A.C., et al., 2002. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26(4):530-536.

Weiss, R.D., et al., 1999. Medication compliance among patients with bipolar disorder and substance use disorder. Journal of Clinical Psychiatry 59(4):172-174.

Weiss, R.D., et al., 2000. Group therapy for patients with bipolar disorder and substance dependence: Results of a pilot study. Journal of Clinical Psychiatry 61(3):361-367.

Young, M.A., et al., 1994. Interactions of risk factors in predicting suicide. American Journal of Psychiatry 151(3):434-435.